Navigation Links
DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology
Date:7/15/2009

LA JOLLA, Calif., July 15 /PRNewswire/ -- DermTech, Inc., a biotechnology company developing non-invasive molecular diagnostics for the early detection of disease plus additional applications, announced that it has entered into the second part of a feasibility study using DermTech's advanced EGIR(TM) technology to help Stiefel identify specific genetic markers involved in acne. The two companies will now move forward with a proof-of-concept study to assess the use of the technology to understand the pathophysiology of acne.

Stiefel is the world's largest independent dermatology company.

"Stiefel is one of the dermatology industry's clear pioneers and is well known for innovation in the field," said George Schwartz, CEO, DermTech. "We are looking forward to together embarking on this study that will employ our advanced, genetic-based technology and believe it will appropriately be the first ever to assess the relationship between genetic changes in the skin over time and the observable clinical effects of a marketed acne treatment."

"Stiefel is committed to using the most advanced, reliable tools for the development and continued refinement of our dermatology products and candidates," said Gavin Corcoran, M.D., Chief Scientific Officer, Stiefel. "We believe that DermTech's EGIR technology, based on the most recent understanding and application of genetics to disease, offers a very strong fit with our mission to introduce breakthrough products."

About DermTech:

Headquartered in La Jolla, California, DermTech International (www.dermtech.com) is developing its proprietary EGIR(TM) (Epidermal Genetic Information Retrieval) technology for genomic-based, non-invasive disease detection, improved pharmaceutical R&D and personalized medicine to help direct appropriate treatment. The company's first product candidate in devel
'/>"/>

SOURCE DermTech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. DermTech and Rady Childrens Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
2. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
3. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
4. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
5. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
6. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
7. Barrier Therapeutics to Merge Into Stiefel Laboratories
8. Stiefel Laboratories Appoints Two New Members to Board of Directors
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
10. Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents
11. Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2VA Announces 2426 Million Construction Contract for Palo Alto 51841 1Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle Aged People at Genetic Risk for Alzheimers Disease 4728 1Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle Aged People at Genetic Risk for Alzheimers Disease 4728 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle Aged People at Genetic Risk for Alzheimers Disease 4728 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle Aged People at Genetic Risk for Alzheimers Disease 4728 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle Aged People at Genetic Risk for Alzheimers Disease 4728 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle Aged People at Genetic Risk for Alzheimers Disease 4728 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle Aged People at Genetic Risk for Alzheimers Disease 4728 7Narconon of Georgia Saves Lives of Orphaned Children in Honduras 51834 1Narconon of Georgia Saves Lives of Orphaned Children in Honduras 51834 2